• Isoprinosine Assays for HSV-1 Egress Research

  2026-09-11

  Isoprinosine, or inosine pranobex, supports a practical bridge between antiviral screening and host-response biology. This workflow pairs concentration-controlled treatment with CLCC1-focused nuclear egress assays to distinguish reduced replication from altered herpesvirus membrane trafficking.

• Patient-Derived Gastric Cancer Assembloid Insights

  2026-09-10

  This 2025 study develops gastric cancer assembloids that combine patient-matched tumor organoids with stromal subpopulations derived from the same tumor tissue. The model captures microenvironment-dependent gene expression and drug-response differences that are missed by tumor-only cultures, supporting more physiologically relevant cancer biology research and personalized screening.

• DAPI Nuclear Stain Solution: Workflow Guide

  2026-09-10

  DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint assessment of membrane integrity. It is suited to fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, but weak cell permeability limits routine live-cell imaging.

• Mubritinib (TAK 165): Complex I Beyond HER2

  2026-09-09

  Mubritinib (TAK 165) is best interpreted as a mitochondrial complex I inhibitor rather than a conventional HER2 probe. This mechanism-centered guide explains how its toxicophore, OXPHOS dependence, and assay controls inform AML, PEL, and cancer biology research.

• Cediranib (AZD2171) in Cancer Research Assays

  2026-09-09

  Cediranib (AZD2171) provides a practical way to probe VEGFR signaling, endothelial responses, and angiogenesis without confusing pathway inhibition with cell killing. This workflow pairs target-engagement measurements with separate growth-inhibition and death metrics for more interpretable cancer research data.

• Geneticin in Metabolic Liver Fibrosis Models

  2026-09-08

  Geneticin, or G418 Sulfate, is more than a stable-cell selection reagent: its translation-inhibitory pressure can materially influence metabolic liver fibrosis assays. This guide connects G418 selection design with the glutamine–GDH–SIRT4 biology described in liver fibrosis research, while distinguishing selection effects from antiviral and disease-specific conclusions.

• EPZ5676: Selective DOT1L Inhibitor Workflow

  2026-09-08

  EPZ5676 is a highly selective DOT1L inhibitor for connecting biochemical SAM-pocket inhibition with H3K79 methylation, transcriptional, and leukemia-cell assays. This workflow shows how to optimize MLL-rearranged models while avoiding common errors in compound handling, assay timing, and cross-domain interpretation.

• 7ACC2: From Lactate Flux to Immune Metabolism

  2026-09-07

  A translational perspective on 7ACC2 as a monocarboxylate transporter 1 inhibitor, linking lactate and mitochondrial pyruvate transport with tumor metabolism, radiosensitization, and emerging macrophage immunometabolism.

• Sorafenib A3009: Reliable Cell Assay Workflows

  2026-09-07

  This scenario-driven guide explains how Sorafenib (BAY-43-9006, SKU A3009) can improve formulation control, dose-response design, and interpretation in cancer cell assays. It connects product-backed potency and solubility data with practical workflows for hepatocellular carcinoma models and kinase-focused research.

• Bay 11-7085: Reading NF-κB Causally

  2026-09-05

  Bay 11-7085 is an NF-κB activation inhibitor that helps separate inflammatory signaling from proliferation and apoptosis. This article interprets the compound through endoplasmic-reticulum-stress biology and shows how to design more defensible assays across disease models.

• c-Myc Tag Peptide: Assay Control to Translation

  2026-09-04

  A thought-leadership guide to using the c-Myc tag Peptide as a precise competition reagent, interpreting transcription-factor abundance, and connecting assay design with translational research questions in cancer and innate immunity.

• TaqI Restriction Endonuclease: Practical DNA Digestion

  2026-09-04

  TaqI provides rapid, sequence-specific cleavage for plasmid DNA, PCR products, and genomic DNA containing its recognition site, supporting cloning, mapping, and routine DNA manipulation. It is for scientific research use only and should not be used for diagnostic or medical procedures.

• Cediranib (AZD2171) In Vitro Workflow Guide

  2026-09-03

  Learn how to use Cediranib (AZD2171) to separate direct VEGFR signaling effects from delayed changes in proliferation and cell death. This practical workflow covers endothelial assays, phospho-Akt measurements, co-culture models, dosing, and troubleshooting for cancer research.

• Growth Arrest vs Cell Death in Cancer Drug Testing

  2026-09-03

  Hannah R. Schwartz’s dissertation, In Vitro Methods to Better Evaluate Drug Responses in Cancer, highlights a major interpretive problem in oncology assays: relative viability and fractional viability are related but non-equivalent measurements. Its findings support time-resolved, endpoint-specific workflows that distinguish proliferative arrest from true cell killing when evaluating therapeutic responses.

• Sulfachloropyridazine: Applied Research Workflows

  2026-09-02

  Sulfachloropyridazine connects target-level DHPS inhibition with antimicrobial susceptibility testing, microbiome profiling, and infection-model research. This practical guide covers solvent handling, assay design, combination studies, and troubleshooting informed by integrated cecal microbiome and metabolomics data.

8094 records 1/540 page Next 12345 下5页 Last page